专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

WO2015128509A1 EXPRESSION CONSTRUCTS AND METHODS FOR SELECTING HOST CELLS EXPRESSING POLYPEPTIDES 审中-公开
标题翻译：用于选择表达多肽的宿主细胞的表达构建体和方法
公开(公告)号：WO2015128509A1
公开(公告)日：2015-09-03
申请号：PCT/EP2015/054331
申请日：2015-03-02
申请人： GLENMARK PHARMACEUTICALS S.A.
发明人： AEBISCHER-GUMY, Christel , MORETTI, Pierre , BERTSCHINGER, Martin
IPC分类号： C12N15/09
CPC分类号： G01N33/56966 , C07K14/705 , C07K16/00 , C07K2317/31 , C07K2317/52 , C07K2317/622 , C12N15/1037 , C12N15/85 , C12N2830/42 , C12N2830/50 , C12P21/00 , G01N33/6854
摘要： The invention relates to an expression construct for the soluble expression of polypeptides in host cells and for the expression of polypeptides on the surface of host cells, using alternative splicing. The amount of cell membrane expression of polypeptides such as antibodies, antibody fragments and bispecific antibodies can be correlated directly to the amount of soluble polypeptide expressed. In the case of bispecific antibodies, cell membrane expression of heterodimer and homodimer products can be correlated directly to the soluble expression of these products, thereby aiding selection of a desired producer clone.
摘要翻译：本发明涉及使用选择性剪接在宿主细胞中多肽可溶性表达和宿主细胞表面上多肽表达的表达构建体。抗体，抗体片段和双特异性抗体等多肽的细胞膜表达量可直接与表达的可溶性多肽的量相关。在双特异性抗体的情况下，异二聚体和同二聚体产物的细胞膜表达可以直接与这些产物的可溶性表达相关，从而有助于选择所需的生产者克隆。

52. 发明申请

WO2015087234A1 BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS 审中-公开
标题翻译：双相异位测量模拟器可用作ROR GAMMA调制器
公开(公告)号：WO2015087234A1
公开(公告)日：2015-06-18
申请号：PCT/IB2014/066720
申请日：2014-12-09
申请人： GLENMARK PHARMACEUTICALS S.A.
发明人： DAS, Sanjib , CHAUDHARI, Sachin Sundarlal , THOMAS, Abraham , PARDESHI, Shailesh Ramesh , DESHMUKH, Vishal Govindrao , WADEKAR, Prashant Dilip , KHAIRATKAR-JOSHI, Neelima , SHAH, Daisy Manish , BAJPAI, Malini
IPC分类号： C07D231/56 , C07D401/04 , C07D209/12 , A61K31/404 , A61K31/416 , A61K31/4162 , A61P37/00
CPC分类号： C07D471/04 , C07D209/12 , C07D231/56 , C07D401/04
摘要： The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X, X 1 , M, R 2 , R 3 , R 4 , R 5 , m, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, neurodegenerative diseases and cancer.
摘要翻译：本公开涉及式（I）的化合物及其药学上可接受的盐，其中X，X1，M，R2，R3，R4，R5，m，n和p如本文所定义，其作为调节剂类视黄醇相关孤儿受体γt（RORγt）。这些化合物预防，抑制或抑制RORγt的作用，因此可用于治疗RORγt介导的疾病，病症，综合征或病症，例如疼痛，炎症，COPD，哮喘，类风湿性关节炎，结肠炎，多发性硬化，神经退行性疾病和癌症。

53. 发明申请

WO2014049003A1 PURIFICATION OF HETERO-DIMERIC IMMUNOGLOBULINS 审中-公开
标题翻译：异源免疫球蛋白的纯化
公开(公告)号：WO2014049003A1
公开(公告)日：2014-04-03
申请号：PCT/EP2013/069989
申请日：2013-09-25
申请人： GLENMARK PHARMACEUTICALS S.A.
发明人： BLEIN, Stanislas , COMPER, Fabrizio , OLLIER, Romain , WASSMANN, Paul
IPC分类号： C07K16/46 , B01D15/38
CPC分类号： C07K16/468 , B01D15/3809 , C07K2317/31 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/565 , C07K2317/567 , C07K2317/622
摘要： The present invention describes novel hetero-dimeric immunoglobulinvariants or fragments thereof, which have reduced or eliminated binding to Protein A, Protein G or both Protein A and Protein G. Also encompassed in the present invention are methods for the selective purification of hetero-dimeric immunoglobulins or fragments thereof using Protein A and Protein G.
摘要翻译：本发明描述了具有减少或消除与蛋白A，蛋白G或蛋白A和蛋白G两者结合的新型异二聚体免疫球蛋白变体或其片段。本发明还包括用于选择性纯化异二聚体免疫球蛋白的方法或其片段使用蛋白A和蛋白G.

54. 发明申请

WO2013153539A1 TRICYCLIC COMPOUNDS AS TEC KINASE INHIBITORS 审中-公开
标题翻译：作为TEC激酶抑制剂的TRICYCLIC化合物
公开(公告)号：WO2013153539A1
公开(公告)日：2013-10-17
申请号：PCT/IB2013/052932
申请日：2013-04-12
申请人： GLENMARK PHARMACEUTICALS S.A.
发明人： CHAUDHARI, Sachin Sundarlal , KUMAR, Sukeerthi , THOMAS, Abraham , KHAIRATKAR-JOSHI, Neelima , SHAH, Daisy Manish
IPC分类号： C07D487/04 , C07D498/04 , A61K31/4188 , A61K31/4985 , A61K31/5383 , A61P37/00
CPC分类号： C07D487/04 , C07D498/04
摘要： The present invention is directed to tricyclic compounds of formula (I) as Tec kinase inhibitors, in particular ITK (interleukin-2 inducible tyrosine kinase) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders mediated by ITK.
摘要翻译：本发明涉及作为Tec激酶抑制剂，特别是ITK（白细胞介素-2诱导型酪氨酸激酶）抑制剂的式（I）的三环化合物。本文还提供了制备本文所述化合物的方法，其合成中使用的中间体，其药物组合物，以及用于治疗或预防由ITK介导的疾病，病症和/或障碍的方法。

55. 发明申请

WO2010103381A1 SPIROCYCLIC PIPERIDINE DERIVATIVES AS TRPM 8 MODULATORS 审中-公开
标题翻译：作为TRPM 8调节剂的螺环哌嗪衍生物
公开(公告)号：WO2010103381A1
公开(公告)日：2010-09-16
申请号：PCT/IB2010/000501
申请日：2010-03-10
申请人： GLENMARK PHARMACEUTICALS S.A. , CHAUDHARI, Sachin, Sundarlal , THOMAS, Abraham , KADAM, Ashok, Bhausaheb , ADIK, Bharat, Gangadhar , DHONE, Sachin, Vasantrao , KHAIRATKAR-JOSHI, Neelima , MUKHOPADHYAY, Indranil
发明人： CHAUDHARI, Sachin, Sundarlal , THOMAS, Abraham , KADAM, Ashok, Bhausaheb , ADIK, Bharat, Gangadhar , DHONE, Sachin, Vasantrao , KHAIRATKAR-JOSHI, Neelima , MUKHOPADHYAY, Indranil
IPC分类号： C07D491/107 , C07D491/113 , C07D498/10 , A61K31/438 , A61K31/537 , A61P29/00
CPC分类号： C07D491/107
摘要： The present invention provides Transient Receptor Potential subfamily M, member 8 (TRPM8) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPM8. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPM8.
摘要翻译：本发明提供式（I）的瞬时受体电位亚族M，成员8（TRPM8）调节剂。特别地，本文所述的化合物可用于治疗或预防由TRPM8调节的疾病，病症和/或病症。本文还提供了制备本文所述化合物的方法，其合成中使用的中间体，其药物组合物，以及用于治疗或预防由TRPM8调节的疾病，病症和/或障碍的方法。

56. 发明申请

WO2010079433A2 PHARMACEUTICAL COMPOSITION THAT INCLUDES A DIPEPTIDYL PEPTIDASE-IV INHIBITOR 审中-公开
标题翻译：一种药物组合物，其中包括一种DIPEPTIDYL PEPTIDASE-IV抑制剂
公开(公告)号：WO2010079433A2
公开(公告)日：2010-07-15
申请号：PCT/IB2010/000202
申请日：2010-01-07
申请人： GLENMARK PHARMACEUTICALS, S.A. , DHUPPAD, Ulhas , ARAVAT, Vajnath , NAVHAT, Someshwar , THOMAS, Abraham , KADAM, Suresh
发明人： DHUPPAD, Ulhas , ARAVAT, Vajnath , NAVHAT, Someshwar , THOMAS, Abraham , KADAM, Suresh
IPC分类号： A61K31/4196 , A61K31/4025 , A61K31/16
CPC分类号： A61K31/4196
摘要： The present patent application relates to a pharmaceutical composition for oral administration that includes a certain pyrrolidine derivative as DPP-IV inhibitor, and a pharmaceutically acceptable excipient. More particularly, the present invention contemplates pharmaceutical compositions that include melogliptin and a pharmaceutically acceptable excipient as well as to processes for preparing the pharmaceutical composition and the use of the composition in reducing glucose level in a subject. The present invention also contemplates an impurity associated with melogliptin.
摘要翻译：本专利申请涉及包含特定的吡咯烷衍生物作为DPP-IV抑制剂的口服药物组合物和药学上可接受的赋形剂。更具体地说，本发明涉及药物组合物，其包括美曲霉素和药学上可接受的赋形剂，以及用于制备药物组合物的方法以及该组合物在降低受试者体内血糖水平方面的用途。本发明还考虑了与曲霉素相关的杂质。

57. 发明申请

WO2010052556A1 TREATMENT WITH ANTI-ALPHA2 INTEGRIN ANTIBODIES 审中-公开
标题翻译：用抗ALPHA2整合抗体治疗
公开(公告)号：WO2010052556A1
公开(公告)日：2010-05-14
申请号：PCT/IB2009/007351
申请日：2009-11-05
申请人： GLENMARK PHARMACEUTICALS S.A. , MOTTL, Harald
发明人： MOTTL, Harald
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , C07K16/46
CPC分类号： C07K16/2839 , A61K2039/505 , C07K16/2842 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： Description of methods for the treatment of cancer. More specifically methods of treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade/follicular non-Hodgkin' s lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade/ follicular NHL; intermediate grade diffuse NHL, high grade immunoblastic NHL; high grade lymphoblastic NHL, high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia,- chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs' syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma and epidermoid carcinoma, by administering antibodies directed to alpha2betal integrin.
摘要翻译：癌症治疗方法的描述。更具体地，涉及治疗选自鳞状细胞癌，肺癌，包括小细胞肺癌，非小细胞肺癌，肺腺癌和鳞状细胞癌，腹膜癌，肝细胞癌癌症，胃癌或胃癌，包括胃肠癌，胰腺癌，成胶质细胞瘤，子宫颈癌，卵巢癌，肝癌，膀胱癌，肝癌，乳腺癌，结肠癌，结肠直肠癌，子宫内膜或子宫癌，唾液腺癌，肾或肾癌症，肝癌，前列腺癌，外阴癌，甲状腺癌，肝癌和各种头颈癌，以及B细胞淋巴瘤，包括低级/滤泡性非霍奇金淋巴瘤（NHL）; 小淋巴细胞（SL）NHL; 中级/滤泡NHL; 中级弥漫性NHL，高级免疫母细胞NHL; 高级别淋巴细胞性NHL，高级小型非裂解细胞NHL; 体积大的NHL; 套细胞淋巴瘤; 艾滋病相关淋巴瘤; 和Waldenstrom的巨球蛋白血症， - 慢性淋巴细胞性白血病（CLL）; 急性淋巴细胞白血病（ALL）; 毛细胞白血病; 慢性成髓细胞白血病; 移植后淋巴增生性疾病（PTLD），以及与phakomatoses相关的异常血管增生，与脑肿瘤，Meigs综合征，黑素瘤，间皮瘤，多发性骨髓瘤，纤维肉瘤，骨肉瘤和表皮样癌相关的水肿，通过施用抗体针对alpha2betal整合素。

58. 发明申请

WO2009144548A1 IMIDAZO [2,1-B] PURINE DERIVATIVES AS TRPA1 MODULATORS 审中-公开
标题翻译： IMIDAZO [2,1-B]作为TRPA1调节剂的嘌呤衍生物
公开(公告)号：WO2009144548A1
公开(公告)日：2009-12-03
申请号：PCT/IB2009/005530
申请日：2009-05-08
申请人： GLENMARK PHARMACEUTICALS S.A. , CHAUDHARI, Sachin, Sundarlal , THOMAS, Abraham , PATIL, Nisha, Parag , DESHMUKH, Vishal, Govindrao , KHAIRATKAR-JOSHI, Neelima , MUKHOPADHYAY, Indranil
发明人： CHAUDHARI, Sachin, Sundarlal , THOMAS, Abraham , PATIL, Nisha, Parag , DESHMUKH, Vishal, Govindrao , KHAIRATKAR-JOSHI, Neelima , MUKHOPADHYAY, Indranil
IPC分类号： C07D487/14
CPC分类号： C07D473/18
摘要： The present invention provides TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPAl (Transient Receptor Potential subfamily A, member 1) modulators. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPAl.
摘要翻译：本发明提供TRPA（瞬时受体电位亚族A）调节剂。特别地，本文所述的化合物可用于治疗或预防由TRPA1（瞬时受体电位亚族A，成员1）调节剂调节的疾病，病症和/或病症。本文还提供了制备本文所述化合物的方法，其合成中使用的中间体，其药物组合物，以及用于治疗或预防由TRPA1调节的疾病，病症和/或障碍的方法。

59. 发明申请

WO2009130560A1 FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS 审中-公开
标题翻译：作为TRPV3调节剂的FUSED PYRIMIDINEONE化合物
公开(公告)号：WO2009130560A1
公开(公告)日：2009-10-29
申请号：PCT/IB2009/005290
申请日：2009-04-15
申请人： GLENMARK PHARMACEUTICALS S.A. , V.S. PRASADARAO, Lingham , SACHIN, Sundarial, Chaudhari , ABRAHAM, Thomas , NEELIMA, Khairatkar-Joshi , VIDYA G., Kattige
发明人： V.S. PRASADARAO, Lingham , SACHIN, Sundarial, Chaudhari , ABRAHAM, Thomas , NEELIMA, Khairatkar-Joshi , VIDYA G., Kattige
IPC分类号： C07D487/04 , C07D498/04 , C07D513/04 , A61K31/519 , A61P29/00
CPC分类号： C07D487/04 , C07D498/04 , C07D513/04
摘要： The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRP V3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
摘要翻译：本发明提供瞬时受体电位香草素（TRPV）调节剂。特别地，本文所述的化合物可用于治疗或预防由TRP V3调节的疾病，病症和/或病症。本文还提供了制备本文所述化合物的方法，其合成中使用的中间体，其药物组合物，以及治疗或预防由TRPV3调节的疾病，病症和/或障碍的方法。

60. 发明申请

WO2009090548A2 3-AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS 审中-公开
标题翻译： 3-AZABICYCLO [3.1.0]作为VANILLOID受体配体的HEXANE衍生物
公开(公告)号：WO2009090548A2
公开(公告)日：2009-07-23
申请号：PCT/IB2009/000075
申请日：2009-01-16
申请人： GLENMARK PHARMACEUTICALS, S.A. , GHARAT, Laxmikant, Atmaram , NARAYANA, Lakshminarayana , KHAIRATKAR-JOSHI, Neelima , KATTIGE, Vidya, G.
发明人： GHARAT, Laxmikant, Atmaram , NARAYANA, Lakshminarayana , KHAIRATKAR-JOSHI, Neelima , KATTIGE, Vidya, G.
IPC分类号： C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D498/04
CPC分类号： C07D417/12 , C07D209/52 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/14 , C07D498/04
摘要： The present invention relates to 3-azabicyclo[3.1.0]hexane derivatives, which are useful as vanilloid receptor (VR) ligands, methods of treating diseases, conditions and/or disorders modulated by vanilloid receptors with them, and processes for preparing them.
摘要翻译：本发明涉及可用作香草素受体（VR）配体的3-氮杂双环[3.1.0]己烷衍生物，用它们治疗由香草素受体调节的疾病，病症和/或障碍的方法及其制备方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式